This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 6850766 results found since Jan 2013.

Pharma scrambles to fast-track drugs
Nature 502, 7469 (2013). http://www.nature.com/doifinder/10.1038/502020a Author: Heidi Ledford ‘Breakthrough therapy’ status is much sought after, but there is confusion about its definition and impact.
Source: Nature - October 1, 2013 Category: Research Authors: Heidi Ledford Tags: News Source Type: research

Regulators adopt more orphan drugs
Nature 508, 7494 (2014). http://www.nature.com/doifinder/10.1038/508016a Author: Sara Reardon Agencies face rising applications for rare-disease therapies resulting from increasingly precise disease definitions.
Source: Nature - April 1, 2014 Category: Research Authors: Sara Reardon Tags: News Source Type: research

Statin Use in Australian Children: A Retrospective Audit of Four Pediatric Hospitals.
CONCLUSIONS: Statins were prescribed to children younger than suggested by current Australian guidelines, with atorvastatin being the preferred statin of choice. Long-term safety studies on the use of statins in children have only included FH patients so far, who are generally healthy besides their raised lipid levels. Further long-term safety studies are needed to include the more vulnerable transplant and renal patients, identified in this audit as being prescribed statins. This can help formulate guidelines for the safest possible use of this class of drugs in the pediatric setting, including the possibility of weight-b...
Source: Paediatric Drugs - August 28, 2014 Category: Pediatrics Authors: Gelissen IC, Nguyen HL, Tiao DK, Ayoub R, Aslani P, Moles R Tags: Paediatr Drugs Source Type: research

Ethics of Drug Studies in the Newborn.
This report describes some of the ethical challenges in conducting drug studies in pediatric patients that must be considered when planning studies and offers some solutions to meet those challenges. Methods of optimal study design should be utilized to limit the number of patients and the number of blood samples. Parental permission should be obtained with equipoise, although the parents of a sick newborn may feel an internal pressure for their child to participate in a study of a new and potentially superior therapy. If appropriate to the study, consent before labor and delivery when parents are less stressed is optimal....
Source: Paediatric Drugs - October 30, 2014 Category: Pediatrics Authors: Ward RM, Sherwin CM Tags: Paediatr Drugs Source Type: research

Projects seek hidden effects of cancer drugs
Nature 516, 7529 (2014). http://www.nature.com/doifinder/10.1038/516021a Author: Heidi Ledford Researchers gather data on innovative uses of cancer treatments.
Source: Nature - December 2, 2014 Category: Research Authors: Heidi Ledford Tags: News Source Type: research

Trends in Antiepileptic Drug Prescriptions for Childhood Epilepsy at a Tertiary Children's Hospital in Korea, 2001-2012.
CONCLUSION: This study provided updated information on AED prescription trends for childhood epilepsy. We found a progressive increase in the use of newer AEDs. However, valproic acid, the only prevalent older AED, continued to be widely prescribed. A high rate of polytherapy among the prescriptions overall raises some safety concerns. PMID: 26400586 [PubMed - as supplied by publisher]
Source: Paediatric Drugs - September 23, 2015 Category: Pediatrics Authors: Cho YS, Ah YM, Jung AH, Kim KJ, Lee JY Tags: Paediatr Drugs Source Type: research

Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.
Abstract Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood and is usually treated with non-steroidal anti-inflammatory drugs or disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate or sulfasalazine. However, not all patients respond to these treatments, and toxicities may limit long-term use or diminish compliance. With advances in pharmacotherapy and the development of new therapeutic agents, there have been improvements in treatment of both systemic and non-systemic JIA, particularly with biologic agents such as anti-tumor necrosis factor (TNF)-α, anti...
Source: Paediatric Drugs - March 3, 2016 Category: Pediatrics Authors: Pagnini I, Bertini F, Cimaz R Tags: Paediatr Drugs Source Type: research

Pharmacotherapy for Dravet Syndrome.
This article reviews treatments for DS, with an emphasis on pharmacotherapy. While many medications are used in treating the seizures associated with DS, these patients typically have medically refractory epilepsy, and polytherapy is often required. First-line agents include valproate and clobazam, although there are supportive data for topiramate, levetiracetam, stiripentol and the ketogenic diet. Other agents such as fenfluramine are promising therapies for Dravet syndrome. Sodium channel-blocking anticonvulsants such as carbamazepine and lamotrigine are generally contraindicated in this syndrome. Nonpharmacologic therap...
Source: Paediatric Drugs - March 10, 2016 Category: Pediatrics Authors: Wallace A, Wirrell E, Kenney-Jung DL Tags: Paediatr Drugs Source Type: research

Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.
Abstract Systemic lupus erythematosus (SLE) is a rare, severe, multisystem autoimmune disorder. Childhood-onset SLE (cSLE) follows a more aggressive course with greater associated morbidity and mortality than adult-onset SLE. Its aetiology is yet to be fully elucidated. It is recognised to be the archetypal systemic autoimmune disease, arising from a complex interaction between the innate and adaptive immune systems. Its complexity is reflected by the fact that there has been only one new drug licensed for use in SLE in the last 50 years. However, biologic agents that specifically target aspects of the immune sys...
Source: Paediatric Drugs - March 12, 2016 Category: Pediatrics Authors: Thorbinson C, Oni L, Smith E, Midgley A, Beresford MW Tags: Paediatr Drugs Source Type: research

Pediatric Glaucoma: Pharmacotherapeutic Options.
Abstract Childhood glaucoma is a major therapeutic challenge for pediatric ophthalmologists and glaucoma specialists worldwide. Management depends on the etiology and age at presentation. A variety of drugs are available for the control of intraocular pressure in children; however, none of these drugs have been licensed by the regulatory agencies for use in children. Furthermore, evidence gained from randomized controlled trials in the pediatric population is sparse, and little is known regarding the use of newer anti-glaucoma preparations. This evidence-based review aims to discuss the available pharmacotherapeut...
Source: Paediatric Drugs - April 18, 2016 Category: Pediatrics Authors: Samant M, Medsinge A, Nischal KK Tags: Paediatr Drugs Source Type: research

Bankruptcy filing worries developers of nanoparticle cancer drugs
Nature 533, 7603 (2016). http://www.nature.com/doifinder/10.1038/533304a Author: Heidi Ledford Financial woes of leading biotech firm highlight challenges of developing innovative therapies.
Source: Nature - May 17, 2016 Category: Research Authors: Heidi Ledford Tags: News Source Type: research

Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA ® (pembrolizumab) Combination Trial
Dateline City: INDIANAPOLIS and KENILWORTH, N.J. INDIANAPOLIS and KENILWORTH, N.J. – Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly’s cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck’s KEYTRUDA® (pembr olizumab) in a Phase I study across multiple tumor types. Language: English read more
Source: Merck.com - Product News - December 10, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news

News from the 60th Livestock Insect Workers Conference
The 60 th Livestock Insect Workers Conference was held in Oklahoma City, OK, June 26-29, 2016. Justin Talley, livestock entomologist at Oklahoma State University, organized and hosted the conference, including a luncheon provided by Whitetails of Oklahoma at a deer farm. Dave Taylor was conferred the 2016 Lifetime Achievement Award in Veterinary Entomology and Bob Pennington is the recipient of the Industry Appreciation Award, both presented by the Livestock Insect Workers Conference. read more
Source: ESA News - July 27, 2016 Category: Biology Authors: rlevine Tags: Members in the News Source Type: research

A tale of two epidemics: drugs harm reduction and tobacco harm reduction in the United Kingdom
Drugs and Alcohol Today, Volume 16, Issue 3 , September 2016. Purpose To compare the response to HIV/AIDS and drug use (drugs harm reduction) with tobacco harm reduction Design/methodology/approach Analysis of historical and contemporary sources, combined with personal knowledge of key stakeholders in the history and development of both fields. Findings Both drugs harm reduction and tobacco harm reduction share a similar objective - to reduce health risks for people who are unwilling or unable to stop using their drug of choice. Both also share a broader public health aim of helping people to make healthier decisions. ...
Source: Drugs and Alcohol Today - July 28, 2016 Category: Addiction Source Type: research

The Cognitive Profile of Ethosuximide in Children.
CONCLUSION: This study suggests the attentional dysfunction resulting in psychomotor slowing and alertness deficits may be regarded as effects of ethosuximide. Although no untreated baseline assessment was available, these effects are comparable to those of other AEDs, and ethosuximide may therefore be considered an AED with only mild effects on cognition. As ethosuximide is a first-line therapy for absence seizures in childhood, and drug-induced cognitive impairment may interfere with development, learning, and academic achievement, these findings are of interest to clinicians who prescribe this drug, especially when info...
Source: Paediatric Drugs - August 23, 2016 Category: Pediatrics Authors: IJff DM, van Veenendaal TM, Debeij-van Hall MH, Jansen JF, de Louw AJ, Majoie MH, Aldenkamp AP Tags: Paediatr Drugs Source Type: research